Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors

Molibresib (GSK525762) is an investigational orally bioavailable small‐molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. In the first‐time‐in‐human BET115521 study of molibresib in patients with solid tumors, thrombocytopenia was the most freq...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnatry, Anu Shilpa, Hanze, Eva, Bergsma, Tim, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124358/
https://www.ncbi.nlm.nih.gov/pubmed/34648693
http://dx.doi.org/10.1002/psp4.12724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124358/
https://www.ncbi.nlm.nih.gov/pubmed/34648693
http://dx.doi.org/10.1002/psp4.12724

Ejemplares similares